CN1041527A - The preparation method of ftibamzone compound liniment - Google Patents
The preparation method of ftibamzone compound liniment Download PDFInfo
- Publication number
- CN1041527A CN1041527A CN 89108540 CN89108540A CN1041527A CN 1041527 A CN1041527 A CN 1041527A CN 89108540 CN89108540 CN 89108540 CN 89108540 A CN89108540 A CN 89108540A CN 1041527 A CN1041527 A CN 1041527A
- Authority
- CN
- China
- Prior art keywords
- ftibamzone
- liniment
- preparation
- present
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the preparation method of a kind of antiviral drugs novel form-ftibamzone compound liniment.The sexually transmitted disease that to be treatment at present cause because of herpesvirus II type that ftibamzone has another name called phthiobuzone and the ideal medicament of viral dermatosis.The present invention is through repeatedly experiment repeatedly, and adopting the mixed solution of propylene glycol and triacetyl glycerine is solvent, adds simultaneously with efficient permeation-promoter azone, and forms phthiobuzonum liniment, and the stability of this liniment reached more than 2 years, and had kept the former effective in cure of this medicine.
Description
The present invention relates to a kind of preparation method of novel form-ftibamzone compound liniment of antiviral drugs.
Ftibamzone (Phtiobuzonum) has another name called phthiobuzone, is a kind of novel antiviral active drug of institute of Materia Medica,Chinese Academy of Medical Sciences in the development seventies, and its structure is:
This medicine is except that trachoma being had the tangible curative effect, the dermatosis that herpesvirus is caused also has definite effect simultaneously, reach more than 80 percent with the cure rate of condyloma acuminatum as the sexually transmitted disease genital herpes that causes with ftibamzone treatment herpesvirus, and in external is treated, find no side effect.Therefore, this medicine obtained the state award for inventions second prize in 88 years.
But because the physicochemical properties instability of this medicine is promptly water insoluble, and all responsive to light and heat, therefore, brought certain difficulty for the production and the clinical practice of this medicine.Be the street drug at present except that 0.1% the ftibamzone suspension collyrium that is used for the treatment of trachoma, the ftibamzone solution of viral dermatosiies such as treatment herpes zoster, condyloma acuminatum, water=1: 1) or be made into the cream external can only be when clinical use, to prepare temporarily, promptly be made into the ftibamzone solution (dimethyl sulfoxine: of 0.1-3.0%.Above-mentioned dosage form all can not solve the stability problem of this medicine, thereby not can manufacture and long preservation, has limited this medicine to a certain extent in clinical extensive use.It is a kind of good to the ftibamzone dissolubility to the objective of the invention is to seek, and the stable ftibamzone new formulation of stable solvent composition, so as for clinical provide a kind of be easy to produce preserve and ftibamzone compound liniment easy to use.
The present invention is by a large amount of experimental studies have found that, is dissolved in the mixed solvent that propylene glycol and triacetyl glycerine form ftibamzone ideal.Ftibamzone not only is easy to dissolving in above-mentioned mixed solvent, and can keep stable.Experimental result proves, accelerated stability effect duration of this liniment reached more than 2 years, and can keep the curative effect of this medicine to viral dermatosis.For better bringing into play the antivirus action of ftibamzone, according to propylene glycol and azone under suitable conditions of mixture ratios, can strengthen the characteristics of drug transdermal effect, the inventor adds an amount of highly effective skin permeation-promoter azone in this liniment, thereby formed complete ftibamzone novel compound liniment, prove that through clinical use the curative effect of this liniment is equal to existing ftibamzone dimethyl sulfoxine aqueous solution preparation.The proportioning of the quality volume of each component is in this liniment:
Ftibamzone 0.1-1.0%
Propylene glycol 5-25%
Azone 0.5-2.0%
Triacetyl glycerine 75-95%
In this liniment preparation method that the present invention proposes, earlier be broken to raw material ftibamzone crystal powder to a certain degree standby, measure an amount of propylene glycol and place container, add azone again, add a certain amount of triacetyl glycerine then and be mixed with mixed solvent, the ftibamzone that crushes is added in the above-mentioned mixed solvent, heating for dissolving to clear and bright light yellow liquid, is chilled to room temperature with it, add mixed solvent to full dose, promptly make the ftibamzone compound liniment.
The present invention compares with the ftibamzone dimethyl sulfoxine aqueous solution of present clinical use, has the following advantages:
1, preparation stabilization, dissolubility is good, and time effect duration is long.
2, be easy to produce in batches and preserve, clinical easy to use.
3, to breakage skin nonirritant.
Embodiment:
1, takes by weighing ftibamzone 2.5 gram and to be crushed to the 80 order left and right sides standby.
2, measure 200 milliliters of propylene glycol, place 1000 milliliters of volumetric flasks, add 10 milliliters of azones again, add triacetyl glycerine then to scale, it is standby to be mixed with clear and bright mixed solvent.
3, with the ftibamzone that crushes, place 1000 milliliters of volumetric flasks, add above-mentioned mixed solvent 900ml, that it is dissolved to is clear and bright faint yellow in heating under the jolting condition, is chilled to room temperature then, adds mixed solvent to 1000 milliliters of full doses, can make the ftibamzone compound liniment, last packing, capping, In Shade keeping in Dark Place.
Claims (3)
1, the preparation method of a kind of antiviral drugs novel form-ftibamzone compound liniment is characterized in that the raw material that adopts is ftibamzone, propylene glycol, triacetyl glycerine and azone etc.
2, the preparation method of ftibamzone compound liniment according to claim 1 is characterized in that the proportioning of the quality volume of each component is:
Ftibamzone 0.1-1.0%
Propylene glycol 5-25%
Azone 0.5-2.0%
Triacetyl glycerine 75-95%
3,, it is characterized in that ftibamzone is dissolved in the mixed solvent of propylene glycol and triacetyl glycerine according to the preparation method of claim 1,2 described ftibamzone compound liniments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89108540 CN1032117C (en) | 1989-11-21 | 1989-11-21 | Process for phthiobuzonum compound liniment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89108540 CN1032117C (en) | 1989-11-21 | 1989-11-21 | Process for phthiobuzonum compound liniment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1041527A true CN1041527A (en) | 1990-04-25 |
| CN1032117C CN1032117C (en) | 1996-06-26 |
Family
ID=4857618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 89108540 Expired - Lifetime CN1032117C (en) | 1989-11-21 | 1989-11-21 | Process for phthiobuzonum compound liniment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1032117C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1063632C (en) * | 1997-10-30 | 2001-03-28 | 王更红 | External use liniment for curing dermatosis |
| CN100469364C (en) * | 2005-07-26 | 2009-03-18 | 中国科学院昆明植物研究所 | Antiviral medicine, prepn. method and application thereof |
| CN101120911B (en) * | 2006-08-11 | 2010-12-22 | 北京协和药厂 | Ftibamzone chrisma with propanediol as co-solvent |
| CN101342174B (en) * | 2008-08-26 | 2011-01-05 | 北京天川军威医药技术开发有限公司 | Phthiobuzonum/diclothane compound topical formulation |
| CN1990470B (en) * | 2005-12-30 | 2011-04-20 | 北京协和药厂 | Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof |
| CN101120913B (en) * | 2006-08-11 | 2011-04-20 | 北京协和药厂 | Ftibamzone chrisma with PEG-200 as co-solvent |
| CN101120912B (en) * | 2006-08-11 | 2011-09-07 | 北京协和药厂 | Ftibamzone chrisma with PEG-400 as co-solvent |
| CN106551897A (en) * | 2015-09-30 | 2017-04-05 | 昆药集团股份有限公司 | A kind of bulleyaconitine A liniment and preparation method and application |
-
1989
- 1989-11-21 CN CN 89108540 patent/CN1032117C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1063632C (en) * | 1997-10-30 | 2001-03-28 | 王更红 | External use liniment for curing dermatosis |
| CN100469364C (en) * | 2005-07-26 | 2009-03-18 | 中国科学院昆明植物研究所 | Antiviral medicine, prepn. method and application thereof |
| CN1990470B (en) * | 2005-12-30 | 2011-04-20 | 北京协和药厂 | Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof |
| CN101120911B (en) * | 2006-08-11 | 2010-12-22 | 北京协和药厂 | Ftibamzone chrisma with propanediol as co-solvent |
| CN101120913B (en) * | 2006-08-11 | 2011-04-20 | 北京协和药厂 | Ftibamzone chrisma with PEG-200 as co-solvent |
| CN101120912B (en) * | 2006-08-11 | 2011-09-07 | 北京协和药厂 | Ftibamzone chrisma with PEG-400 as co-solvent |
| CN101342174B (en) * | 2008-08-26 | 2011-01-05 | 北京天川军威医药技术开发有限公司 | Phthiobuzonum/diclothane compound topical formulation |
| CN106551897A (en) * | 2015-09-30 | 2017-04-05 | 昆药集团股份有限公司 | A kind of bulleyaconitine A liniment and preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1032117C (en) | 1996-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4153689A (en) | Stable insulin preparation for nasal administration | |
| EP1930002B1 (en) | Use of hydroxybenzoic acid ester compounds for the manufacture of a medicament for the prevention and treatment of hpv infection | |
| JP5498521B2 (en) | Radiation damage reducing agent | |
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN1032117C (en) | Process for phthiobuzonum compound liniment | |
| CN114404430B (en) | A composition containing Pulsatillae saponin B4 as effective component for promoting hair growth | |
| CN114288309B (en) | A composition containing pulsatilla saponin B5 as effective component for promoting hair growth | |
| US20100317604A1 (en) | Forsythiaside injection preparation and preparative method thereof | |
| WO2021036058A1 (en) | Teriparatide sustained release gel injection solution and preparation method therefor | |
| KR100894364B1 (en) | Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field | |
| KR101740163B1 (en) | Use of 3-n-butyl-1-isoindolinone in preparation of drugs for preventing and treating cerebral infarction | |
| CN112618591B (en) | A pharmaceutical composition containing total flavonoids of herba Blumeae Balsamiferae | |
| CN102836211A (en) | Salvia miltiorrhiza-lobed kudzuvine root eyesight improving in-situ gel | |
| CN110433132B (en) | Tetrandrine nasal preparation for treating post-traumatic stress disorder | |
| RU2625039C1 (en) | Pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol, method for its production and applications for cardiovascular diseases treatment | |
| CN102258507A (en) | Ibuprofen-containing pharmaceutical composition and its preparation method and application | |
| CN100360132C (en) | Combination of medication for antivirus in use for eye region and preparation method | |
| CN109010268A (en) | A kind of ophthalmic composition and preparation method thereof improving chloramphenicol stability | |
| CN113116916B (en) | A pharmaceutical composition for treating gynecological diseases, and its preparation method | |
| WO2023138280A1 (en) | Hair growth promoting composition, hair growth promoting drug and use | |
| CN107616977A (en) | A kind of compound preparation for treating antimigraine and preparation method thereof | |
| CN114099428B (en) | Idebenone oral liquid insensitive to temperature and preparation method thereof | |
| CN108355138A (en) | A kind of application of azone in drug transdermal promotees to ooze | |
| NL2033322B1 (en) | Baicalin-calcium alginate thermosensitive nanogel as well as preparation method and application thereof | |
| ES2628709T3 (en) | Composition to control and improve female and male gametogenesis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 19960626 |